Skip to main content

Table 1 Background characteristics of patients treated with SCIG push

From: Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review

 IVIG naïve (N = 27)IVIG prior (N = 35)
Age at SCIG initiation, mean (range)50 (30–78)51 (26–80)
SCIG dose [g/kg/week] (range)0.14 (0.06–0.29)0.15 (0.09–0.22)
Sex
 Female17 (63%)23 (66%)
Diagnosis
 CVID13 (48%)11 (31%)
 IgGSD8 (30%)13 (37%)
 Hypogammaglobulinemia NOS5 (19%)7 (20%)
 SAD1 (3%)
 X-linked agammaglobulinemia1 (3%)
 Unspecified humoral immunodeficiency1 (4%)2 (6%)
Comorbidities
 Bronchiectasis, CRS, or both15 (56%)16 (46%)
  1. IGGSD IgG subclass deficiency, CVID common variable immunodeficiency, SAD specific antibody deficiency, NOS Not otherwise specified, CRS chronic rhinosinusitis, g  grams, kg kilograms